The S&P 500 has witnessed 18.5% growth in the said time frame.The renowned rapid diagnostic testing solutions provider has a market capitalization of $2.84 billion. QuidelOrtho's earnings yield of 4.3% compares favorably with the industry's 0.7%. The company's earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average surprise being 31.73%.Image Source: Zacks Investment ResearchLet's delve deeper.UpsidesStrong Product Portfolio: We are upbeat about QuidelOrtho's current product clientele.